ADARx Pharmaceuticals, Inc.
American late-clinical stage biotechnology company developing siRNA therapeutics, listed on Nasdaq in September 2026.
Company Type
public
Founded
2019
Headquarters
San Diego, California, United States
Stock
Nasdaq: ADRX
Employees
~250
Primary Market
United States
Shop ADARx Pharmaceuticals, Inc. Brands
Disclosure: We may earn commission from purchases
About ADARx Pharmaceuticals, Inc.
What does ADARx do?
ADARx develops siRNA therapeutics that silence disease-driving genes. Its pipeline targets cardiovascular, metabolic, complement, and neurological conditions using delivery technology that reaches tissues beyond the liver.
Is ADARx publicly traded?
Yes. ADARx listed on Nasdaq under ticker ADRX on September 24, 2026, raising approximately $446 million.
Who founded ADARx?
Zhen Li co-founded the company in December 2019 and serves as president and CEO. She previously led siRNA research at Arrowhead Pharmaceuticals and Merck.
Where is ADARx headquartered?
ADARx is headquartered at 5871 Oberlin Drive in San Diego, California.
Who owns ADARx?
After the IPO, ADARx is owned by public shareholders, founders, employees, and venture investors. AbbVie holds approximately 4.9% through an IPO investment capped at $100 million.
When did ADARx IPO?
ADARx priced its IPO on September 24, 2026, selling 26.25 million shares at $17 each for gross proceeds of approximately $446.3 million.
History of ADARx Pharmaceuticals, Inc.
Zhen Li co-founded ADARx in December 2019 in San Diego and has served as president and CEO since January 2020. The founding team drew heavily from Arrowhead Pharmaceuticals, the established siRNA company where Li had led discovery and non-clinical development.
The company raised private capital through the early 2020s, building a pipeline of siRNA candidates across genetic, cardiovascular, and metabolic disease. The COVID-era biotech market downturn tested the sector broadly, but ADARx continued clinical advancement.
In 2025 and 2026 the company advanced lead programs into late-stage development, positioning it for public markets. The September 2026 IPO priced 26.25 million shares at $17, above the indicated range, raising approximately $446.3 million.
A notable feature of the offering was AbbVie's participation. The pharmaceutical company agreed to buy shares at the IPO price that would give it approximately 4.9% ownership, subject to a $100 million cap. Strategic investment by a major pharma company in an IPO is a validation signal the market noted.
Brands Owned by ADARx Pharmaceuticals, Inc.
ADARx Pharmaceuticals, Inc. owns 1 brand in our database. Explore the ownership tree below — click categories to expand and see individual brands.
ADARx Pharmaceuticals, Inc.
public · Founded 2019 · San Diego, California, United States
1
brands
Stock Information
ADARx Pharmaceuticals, Inc. Ownership: Pros & Cons
Advantages
- +Deep siRNA technical leadership from Arrowhead and Merck lineage
- +$446 million IPO provides multi-year funding runway
- +AbbVie's strategic stake validates the platform
- +Delivery technology targets diseases beyond the liver
Considerations
- -Clinical-stage biotech with no product revenue
- -Drug development carries high failure risk
- -Competition from Alnylam and Arrowhead is established and better funded
- -SiRNA field faces patent and IP disputes among incumbents
Frequently Asked Questions About ADARx Pharmaceuticals, Inc.
What does ADARx do?
ADARx develops siRNA therapeutics that silence disease-driving genes. Its pipeline targets cardiovascular, metabolic, complement, and neurological conditions using delivery technology that reaches tissues beyond the liver.
Is ADARx publicly traded?
Yes. ADARx listed on Nasdaq under ticker ADRX on September 24, 2026, raising approximately $446 million.
Who founded ADARx?
Zhen Li co-founded the company in December 2019 and serves as president and CEO. She previously led siRNA research at Arrowhead Pharmaceuticals and Merck.
Where is ADARx headquartered?
ADARx is headquartered at 5871 Oberlin Drive in San Diego, California.
Who owns ADARx?
After the IPO, ADARx is owned by public shareholders, founders, employees, and venture investors. AbbVie holds approximately 4.9% through an IPO investment capped at $100 million.
When did ADARx IPO?
ADARx priced its IPO on September 24, 2026, selling 26.25 million shares at $17 each for gross proceeds of approximately $446.3 million.
Sources & Further Reading
Jobs at ADARx Pharmaceuticals, Inc.
Latest News About ADARx Pharmaceuticals, Inc.
Related Articles About ADARx Pharmaceuticals, Inc.
View more articles
Monthly IPO Roundup: October 2026 -- September's Biggest Listings
September 2026 IPOs: Shein raised $1.7B in Hong Kong's largest listing of the year and closed flat, NSE India debuted at a $46B valuation in the country's second-largest IPO, Enflame surged 179% in Shanghai, and Anthropic's $2 trillion S-1 surfaced. Full recap.
Iconic British Brands Now Foreign-Owned
Cadbury is American (Mondelez). Rolls-Royce cars are German (BMW). Jaguar Land Rover is Indian (Tata). HP Sauce is American-Belgian (Kraft Heinz). Discover iconic British brands now foreign-owned. Explore our database.
Monthly M&A Roundup: September 2026 Brand Ownership Changes
September 2026's biggest deals: Nvidia signed its $12.9B Hugging Face acquisition, GE Aerospace agreed to buy CPP for $11.75B, AMD acquired World Labs for $8.2B, Royal Caribbean took a $3B stake in Sandals, LVMH sold Marc Jacobs, and Nestle offloaded its vitamins business for $1B. Full breakdown.
Related Companies to ADARx Pharmaceuticals, Inc.
View more companies
STARZ Entertainment Corp.
Publicly traded American premium entertainment company operating the STARZ streaming and cable network, focused on women and underrepresented audiences. Separated from Lionsgate in May 2025.
1 brand in portfolio
Cardinal Health
American multinational healthcare services company specializing in pharmaceutical distribution, medical products, specialty pharmacy, and at-home healthcare solutions. One of the largest healthcare companies globally by revenue.
4 brands in portfolio
Cencora Inc.
American pharmaceutical distribution company and one of the largest healthcare companies globally by revenue, formerly known as AmerisourceBergen, with FY2025 revenue of $321.3 billion.
7 brands in portfolio
Centene Corporation
American multinational healthcare enterprise and the largest Medicaid managed care organization in the United States, providing managed care services and health insurance for government-sponsored healthcare programs, with FY2025 revenue of $194.8 billion.
6 brands in portfolio
CVS Health Corporation
American integrated healthcare company operating CVS Pharmacy, Aetna health insurance, CVS Caremark pharmacy benefits management, and MinuteClinic, publicly traded on the NYSE.
10 brands in portfolio
Elevance Health Inc.
American health benefits company providing medical, pharmacy, behavioral, and dental insurance products, formerly known as Anthem, headquartered in Indianapolis, Indiana.
4 brands in portfolio